Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.37 |
| ▸ | NQO2 | P16083 | 2/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.36 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.36 |
| ▸ | KIF11 | P52732 | 4/20 | 0.36 |
| ▸ | SLC6A1 | P30531 | 2/20 | 0.35 |
| ▸ | SLC6A11 | P48066 | 1/20 | 0.35 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27081272 | 1.00 | MEN1 (0.38) | MEN1KMT2APSMB5NQO2MTNR1A | |
| SCHEMBL27081364 | 0.82 | KIF11 (0.37) | MEN1KMT2AKIF11 | |
| SCHEMBL27081368 | 0.82 | KIF11 (0.37) | MEN1KMT2AKIF11 | |
| SCHEMBL8843146 | 0.81 | ALDH1A1 (0.47) | MEN1KMT2AKIF11 | |
| SCHEMBL27081237 | 0.81 | ALDH1A1 (0.47) | MEN1KMT2AKIF11 | |
| SCHEMBL27081257 | 0.79 | KIF11 (0.41) | KIF11SLC6A1SLC6A11 | |
| SCHEMBL27081261 | 0.79 | KIF11 (0.41) | KIF11SLC6A1SLC6A11 | |
| SCHEMBL8843117 | 0.77 | KIF11 (0.35) | MEN1KMT2ANQO2MTNR1AMTNR1B | |
| SCHEMBL24127770 | 0.74 | MTNR1A (0.41) | NQO2MTNR1AMTNR1BKIF11SLC6A1 | |
| SCHEMBL8843202 | 0.73 | MTNR1A (0.39) | KMT2ANQO2MTNR1AMTNR1BKIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240209018-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | GENSCRIPT USA INC. | 2024-06-27 | — | — | US | disclosed |
| EP-4313984-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | Genscript USA Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022204102-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | GENSCRIPT USA INC. (US) | 2022-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240209018-A1 | UNIVERSAL LINKER REAGENTS FOR DNA SYNTHESIS | RNGTT, DTYMK, UNG | MEN1 2038/4885KMT2A 1002/4885PSMB5 3551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.